Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 8.29M | 2.94M | 4.68M | 1.80M | 6.03M |
Gross Profit | 7.66M | 1.22M | 1.91M | 539.50K | 4.23M |
EBITDA | -9.63M | -15.25M | -15.80M | -21.42M | -14.40M |
Net Income | -8.16M | -15.64M | -16.15M | -19.73M | -14.68M |
Balance Sheet | |||||
Total Assets | 36.81M | 52.09M | 66.17M | 73.24M | 39.08M |
Cash, Cash Equivalents and Short-Term Investments | 23.36M | 35.18M | 49.92M | 60.50M | 30.05M |
Total Debt | 3.53M | 8.27M | 8.19M | 1.17M | 1.57M |
Total Liabilities | 8.70M | 17.27M | 17.78M | 10.94M | 7.75M |
Stockholders Equity | 28.12M | 34.81M | 48.39M | 62.30M | 31.33M |
Cash Flow | |||||
Free Cash Flow | -7.07M | -14.15M | -14.00M | -15.05M | -10.90M |
Operating Cash Flow | -6.98M | -13.53M | -13.16M | -14.81M | -10.78M |
Investing Cash Flow | -89.00K | -610.00K | -836.00K | -246.00K | -125.00K |
Financing Cash Flow | -4.75M | -695.00K | 3.23M | 46.30M | -584.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
56 Neutral | AU$41.04M | ― | -36.95% | ― | ― | 11.11% | |
55 Neutral | AU$40.99M | ― | -43.63% | ― | -67.07% | -47.32% | |
51 Neutral | $7.39B | 0.36 | -62.86% | 2.37% | 15.48% | -2.68% | |
47 Neutral | AU$46.97M | ― | -143.22% | ― | ― | -4.06% | |
46 Neutral | AU$14.28M | ― | -64.72% | ― | 139.19% | 33.33% | |
43 Neutral | AU$39.54M | ― | -75.39% | ― | ― | 44.29% | |
36 Underperform | AU$35.07M | ― | -42.50% | ― | ― | 80.96% |
Starpharma Holdings Limited has made significant strides in maximizing the value of its DEP® assets and expanding its research collaborations. The company has been actively engaging with global stakeholders and showcasing its dendrimer technology at major conventions, while also advancing its radiotheranostics program and preparing for product launches in new markets. Despite challenges such as geopolitical complexities and a shifting oncology landscape, Starpharma remains focused on strategic execution and partnership opportunities to enhance shareholder value and improve patient outcomes.
Starpharma Holdings Limited announced the cessation of 716,375 performance rights due to unmet conditions, impacting its issued capital structure. This development may affect stakeholders’ perceptions of the company’s operational progress and could influence its market positioning by highlighting challenges in meeting performance targets.
Starpharma Holdings Limited has experienced a change in the interests of its substantial holder, UIL Limited, which has decreased its voting power from 8.02% to 6.39%. This change in voting power may impact the company’s governance dynamics and influence within the market, as substantial holders often have significant sway in decision-making processes.
Robmar Investments Pty Limited has filed a notice of change of interests, indicating a shift in its substantial holding in Starpharma Holdings Limited. This change could impact Starpharma’s shareholder dynamics and potentially influence its strategic decisions, reflecting broader market movements or shifts in investor confidence.